With over 800 China-based and over 50 US-based R&D staff, our R&D team focuses on the research and development of generic and innovative small and large molecule drugs covering the following therapeutic areas:
● Adjuvant Oncology
● Cerebrovascular and Cardiovascular System
● Infectious Diseases
Our R&D team is fully integrated, covering functions of early stage development, API and formulation research, clinical studies, domestic and international regulatory affairs and business development. A fully functional and comprehensive team ensures traceable research quality and integrity.
Qilu has also set up three US-based R&D centers based in Seattle, WA, Boston, MA, and San Francisco, CA. With strong biotechnology background, experiences and resources, the US R&D centers are now responsible for innovative biologics R&D.
Recently opened in Zhangjiang District, Shanghai, Qilu Shanghai Institute of Innovative Pharmaceutical R&D plans to utilize the great potential and pharmaceutical resources in the Chinese economy capital, undertaking more innovative research programs and work for Qilu.